CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice

Kidney International

Volumn 78, Issue 9, 2010, Pages 883-894

  Kang, Young Sun ^a   Lee, Mi Hwa ^a   Song, Hye Kyoung ^a   Ko, Gang Jee ^a   Kwon, Oh Sung ^a   Lim, Tae Kyung ^a   Kim, Sung Hwan ^a   Han, Sang Youb ^b   Han, Kum Hyun ^b   Lee, Ji Eun ^c   Han, Jee Young ^d   Kim, Hyoung Kyu ^a   Cha, Dae Ryong ^a  

^a Korea University   (South Korea)

^b Inje University   (South Korea)

^c Wonkwang University   (South Korea)

^d Inha University   (South Korea)

Author keywords

HOMA IR; LPO; MCP 1; renal lipid metabolism

Indexed keywords

8 ISOPROSTANE; ALBUMIN; CHOLESTEROL; INSULIN; LIPID; LIPID HYDROPEROXIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; RS 04393; RS 504393; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; HOMEOSTASIS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; LIPID METABOLISM; MALE; METABOLIC PARAMETERS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINARY EXCRETION;

EID: 77958102050     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.263     Document Type: Article

References (48)

1. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-296.
2. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006; 17: 368-377.
3. Mora C, Navarro JF. Inflammation and diabetic nephropathy. Curr Diab Rep 2006; 6: 463-468.
4. Bohle A, Wehrmann M, Bogenschutz O et al. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991; 187: 251-259.
5. Furuta T, Saito T, Ootaka T et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993; 21: 480-485.
6. Han SY, Kim CH, Kim HS et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372.
7. Sassy-Prigent C, Heudes D, Mandet C et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000; 49: 466-475.
8. Ruster C, Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci 2008; 13: 944-955.
9. Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000; 11: 152-176.
10. Kanamori H, Matsubara T, Mima A et al. Inhibition of MCP-1/CCR2 pathway ameliorates the development ofdiabetic nephropathy. Biochem Biophys Res Commun 2007; 360: 772-777.
11. Giunti S, Tesch GH, Pinach S et al. Monocyte chemoattractant protein-1 has prosclerotic effect both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 2008; 51: 198-207.
12. Chow FY, Nikolic-Paterson DJ, Ma FY et al. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007; 50: 471-480.
13. Cha DR, Kang YS, Han SY et al. Role of aldosterone in diabetic nephropathy. Nephrology 2005; 10(Suppl 2): S37-S39.
14. Segerer S, Cui Y, Hudkins KL et al. Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomerulonephritis. J Am Soc Nephrol. 2000. 11. 2231-2242
15. Vielhauer V, Anders HJ, Mack M et al. Obstructive nephropathy in the mouse: progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2-and 5-positive leukocytes.J Am Soc Nephrol 2001; 12: 1173-1187.
16. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
17. Ferrante Jr AW. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 2007; 262: 408-414.
18. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006; 580: 2917-2921.
19. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007; 447: 1116-1120.
20. Dalla Vestra M, Mussap M, Gallina P et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16(Suppl. 1): S78-S82.
21. Wada T, Furuichi K, Sakai N et al. Up-regulation of monocyte chemo-attractant protein-1 in tubulo-interstitial lesions of human diabetic nephropathy. Kidney Int 2000; 58: 1492-1499.
22. Tamura Y, Sugimoto M, Murayama T et al. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol 2008; 28: 2195-2201.
23. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
24. Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci2009; 117: 95-109.
25. Schmitz G, Grandl M. Lipid homeostasis in macrophages-implications for atherosclerosis. Rev Physiol Biochem Pharmacol 2008; 160: 93-125.
26. Unger RH. Lipotoxic diseases. Annu Rev Med 2002; 53: 319-336.
27. Duncan BB, Schmidt MI, Pankow JS et al. Atherosclerosis Risk in Communities Study. Low-grade systemic inflammation and the development oftype 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes 2003; 52: 1799-1805.
28. Pradhan AD, Manson JE, Rifai N et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
29. Schmidt MI, Duncan BB, Sharrett AR et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999; 353: 1649-1652.
30. Spranger J, Kroke A, Mohlig M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
31. Haffner S. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-1572.
32. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850.
33. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
34. Shimomura I, Funahashi T, Takahashi M et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-803.
35. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
36. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.
37. Kamei N, Tobe K, Suzuki R et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281: 26602-26614.
38. Kanda H, Tateya S, Tamori Y et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505.
39. Wei R, Phillips TM, Sternberg EM. Specific up-regulation of CRH or AVP secretion by acetylcholine or lipopolysaccharide in inflammatory susceptible Lewis rat fetal hypothalamic cells. J Neuroimmunol 2002; 131: 31-40.
40. Hauner H, Rohrig K, Spelleken M et al. Development of insulin-responsive glucose uptake and GLUT4 expression in differentiating human adipocyte precursor cells. Int J Obes Relat Metab Disord 1998; 22: 448-453.
41. Marin P, Andersson B, Ottosson M et al. The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism 1992; 41: 1242-1248.
42. Ninichuk V, Clauss S, Kulkarni O et al. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol 2008; 172: 628-637.
43. Chen A, Mumick S, Zhang C et al. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res 2005; 13: 1311-1320.
44. Park CW, Kim HW, Ko SH et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18: 1227-1238.
45. Proctor G, Jiang T, Iwahashi M et al. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 2006; 55: 2502-2509.
46. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
47. Lee MH, Song HK, Ko GJ et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 2008; 74: 890-900.
48. Fasshauer M, Klein J, Neumann S. Isoproterenol inhibits resistin gene expression through a G(S)-protein-coupled pathway in 3T3-L1 adipocytes. FEBS Lett 2001; 500: 60-63.